TNSN08461A1 - Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain. - Google Patents

Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain.

Info

Publication number
TNSN08461A1
TNSN08461A1 TNP2008000461A TNSN08461A TNSN08461A1 TN SN08461 A1 TNSN08461 A1 TN SN08461A1 TN P2008000461 A TNP2008000461 A TN P2008000461A TN SN08461 A TNSN08461 A TN SN08461A TN SN08461 A1 TNSN08461 A1 TN SN08461A1
Authority
TN
Tunisia
Prior art keywords
methylphenylsulfanyl
piperidine
phenyl
treatment
neuropathic pain
Prior art date
Application number
TNP2008000461A
Inventor
Benny Bang-Andersen
Andre Faldt
Tine Bryan Stensbol
De Diego Heidi Lopez
Silke Miller
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2007/050076 external-priority patent/WO2007144006A1/en
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of TNSN08461A1 publication Critical patent/TNSN08461A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/12—Glutaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/08—Lactic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine and salts thereof are provided e.g. for the treatment of neuropathic pain.
TNP2008000461A 2006-06-16 2008-11-17 Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain. TNSN08461A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200600816 2006-06-16
DKPA200700423 2007-03-20
PCT/DK2007/050076 WO2007144006A1 (en) 2006-06-16 2007-06-15 Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain

Publications (1)

Publication Number Publication Date
TNSN08461A1 true TNSN08461A1 (en) 2010-04-14

Family

ID=39722478

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2008000461A TNSN08461A1 (en) 2006-06-16 2008-11-17 Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain.

Country Status (15)

Country Link
JP (1) JP2014098017A (en)
KR (1) KR101472595B1 (en)
AR (1) AR061480A1 (en)
AT (1) ATE508115T1 (en)
BR (1) BRPI0712758A2 (en)
CA (1) CA2784304A1 (en)
DE (1) DE602007014372D1 (en)
DK (1) DK2044020T3 (en)
MY (1) MY150698A (en)
NZ (1) NZ572856A (en)
PT (1) PT2044020E (en)
RS (1) RS51687B (en)
SI (1) SI2044020T1 (en)
TN (1) TNSN08461A1 (en)
TW (1) TWI444365B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101972931B1 (en) 2017-10-19 2019-04-26 재단법인대구경북과학기술원 Balloon type ecog measuring device and its manufacturing method
CN116930385B (en) * 2023-08-08 2024-02-20 北京爱思益普生物科技股份有限公司 Method for measuring concentration of compound in high-salt-concentration preparation
CN117305360B (en) * 2023-09-15 2024-09-24 江南大学 Mammalian cell nucleus transfection liquid, preparation method thereof and application thereof in cell nucleus delivery

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (en) * 2001-10-04 2008-02-11 Х. Луннбек А/С Derivated of phenylpiperazine as serotonin reuptake inhibitorS
EA016054B1 (en) * 2006-06-16 2012-01-30 Х. Лундбекк А/С Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain

Also Published As

Publication number Publication date
MY150698A (en) 2014-02-28
JP2014098017A (en) 2014-05-29
KR101472595B1 (en) 2014-12-15
TWI444365B (en) 2014-07-11
BRPI0712758A2 (en) 2012-09-25
AR061480A1 (en) 2008-08-27
CA2784304A1 (en) 2007-12-21
TW200817329A (en) 2008-04-16
PT2044020E (en) 2011-05-12
NZ572856A (en) 2012-02-24
RS51687B (en) 2011-10-31
DE602007014372D1 (en) 2011-06-16
ATE508115T1 (en) 2011-05-15
SI2044020T1 (en) 2011-06-30
KR20090018630A (en) 2009-02-20
DK2044020T3 (en) 2011-08-15

Similar Documents

Publication Publication Date Title
IL195310A0 (en) Crystalline forms of 4-[2-(4-methylphenylsulfanyl)- phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
NO343929B3 (en) 1- [2- (2,4-dimethylphenylsulfanyl-phenyl] -piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5HT1A activity for the treatment of cognitive pain
WO2008113360A3 (en) 4- [2- (4-methylphenylsulfanyd-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of adhd, melancholia, treatment resistent depression or residual symptoms in depression
IL192242A0 (en) Improved process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides
EP2358691B8 (en) Process for the preparation of piperazine compounds and hydrochloride salts thereof
CY1112345T1 (en) Polymorphic Form of 4- [3- (4-Cyclopropanecarbonyl-Piperazine-1-Carbonyl) -4-Fluoro-Benzyl] -2H-Phthalazin-1-One
EP2220074A4 (en) 3,5-substituted indole compounds having nos and norepinephrine reuptake inhibitory activity
CO6361988A2 (en) CRYSTAL FORM OF A COMPOUND OF 4- [2- (2-FLUOROPHENOXIMETHYL) PHENYL] PIPERIDINE.
IL192241A0 (en) Improved process for the preparation of 4-(benzimidazolylmethylamino)-benzamides and the salts thereof
MX2010003989A (en) Composition 064.
TNSN08461A1 (en) Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain.
BRPI0816221A2 (en) Crystalline Form 1 of 2 - ((r) -2-methylpyrrolidin-2-ol) -1h-benzimidazol-4-carboxamide
HK1140949A1 (en) Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl) phenyl]piperidine 4-[2-(4-)-]
UA95801C2 (en) Crystalline forms of 4-[2- (4-methylphenylsulfanyl) -phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
EA201000611A1 (en) 4,4-DESIGNED PIPERIDINES
AU2008339005A8 (en) 3,4-substituted pyrrolidine beta-secretase inhibitors for the treatment of Alzheimer's disease
BRPI0715711A2 (en) L-GLUTAMIC ACID PRODUCING BACTERIA, AND, METHODS FOR PRODUCING L-GLUTAMIC ACID, AND FOR IMPROVING THE GROWTH OF A L-GLUTAMIC ACID PRODUCING MICROORGANISM UNDER ACID CONDITIONS
UA101005C2 (en) Therapeutic uses of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine for the treatment of depression associated with irritable bowel syndrome